Moleculin Biotec Financials
Moleculin Biotec (MBRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing rather than operations remains the core engine, as cash burn persistently outpaces the company’s internal funding.
Across FY2023-FY2025, free cash flow stayed near-$23M a year and almost matched operating cash flow because capital spending was minimal, so reinvestment needs are not what is consuming cash. Cash recovered to$8.9M only because financing inflow of$27.3M exceeded that burn.
Liquidity looks repaired but dependent. Cash ended FY2025 at
The spending mix is still development-led: FY2025 R&D was
Financial Health Signals
Moleculin Biotec does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Moleculin Biotec scores -15.63, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($11.8M) relative to total liabilities ($7.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Moleculin Biotec passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Moleculin Biotec reported a net loss of $33.6M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Moleculin Biotec generated $0 in revenue in fiscal year 2025.
Moleculin Biotec's EBITDA was -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.7% from the prior year.
Moleculin Biotec reported -$33.6M in net income in fiscal year 2025. This represents a decrease of 28.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Moleculin Biotec recorded an outflow of $22.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 4.8% from the prior year.
Moleculin Biotec held $8.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Moleculin Biotec's ROE was -223.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 8.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Moleculin Biotec invested $15.9M in research and development in fiscal year 2025. This represents a decrease of 10.4% from the prior year.
Moleculin Biotec reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
MBRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| R&D Expenses | N/A | $15.9M-10.4% | $17.7M-9.0% | $19.5M+2.7% | $19.0M+31.6% | $14.4M+13.0% | $12.8M+15.8% | $11.0M+13.2% | $9.7M+114.0% | $4.5M+203.8% | $1.5M | N/A |
| SG&A Expenses | N/A | $9.1M+3.8% | $8.8M-12.3% | $10.0M-13.2% | $11.5M+37.6% | $8.4M+23.6% | $6.8M+7.5% | $6.3M+20.7% | $5.2M+27.8% | $4.1M+71.8% | $2.4M | N/A |
| Operating Income | N/A | -$25.1M+5.8% | -$26.6M+10.1% | -$29.6M+3.3% | -$30.6M-33.4% | -$23.0M-16.3% | -$19.7M-12.7% | -$17.5M-16.6% | -$15.0M-73.6% | -$8.7M-122.8% | -$3.9M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | $240K-21.6% | $306K+2253.8% | $13K0.0% | $13K+225.0% | $4K | $0-100.0% | $43K | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0+100.0% | -$229K | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$33.6M-28.8% | -$26.0M+12.5% | -$29.8M-2.6% | -$29.0M-82.6% | -$15.9M+8.4% | -$17.4M-31.4% | -$13.2M-11.2% | -$11.9M-21.1% | -$9.8M-149.7% | -$3.9M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MBRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.1M+30.7% | $16.9M-55.7% | $38.2M-33.4% | $57.4M-31.7% | $84.1M+189.7% | $29.0M+15.0% | $25.2M+28.8% | $19.6M+0.5% | $19.5M+18.8% | $16.4M+58256.8% | $28K |
| Current Assets | $9.7M+86.5% | $5.2M-80.2% | $26.3M-42.4% | $45.6M-37.1% | $72.5M+321.5% | $17.2M+27.5% | $13.5M+69.1% | $8.0M-4.0% | $8.3M+59.0% | $5.2M+18489.6% | $28K |
| Cash & Equivalents | $8.9M+107.5% | $4.3M-81.8% | $23.6M-45.4% | $43.1M-39.1% | $70.9M+367.3% | $15.2M+41.3% | $10.7M+50.5% | $7.1M-7.5% | $7.7M+54.1% | $5.0M+17782.1% | $28K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $1K-98.2% | $56K | N/A | N/A | N/A |
| Total Liabilities | $7.1M+24.5% | $5.7M-52.9% | $12.1M+132.2% | $5.2M+2.6% | $5.1M-54.8% | $11.3M+16.6% | $9.7M+81.9% | $5.3M+124.7% | $2.4M+65.0% | $1.4M+85.4% | $773K |
| Current Liabilities | $6.9M+27.9% | $5.4M-21.4% | $6.8M+41.4% | $4.8M+33.0% | $3.6M+24.0% | $2.9M-18.2% | $3.6M-7.9% | $3.9M+75.1% | $2.2M+64.7% | $1.3M+74.0% | $773K |
| Total Equity | $15.0M+33.9% | $11.2M-63.8% | $30.9M-40.7% | $52.2M-33.9% | $79.0M+344.8% | $17.8M+14.1% | $15.6M+9.1% | $14.3M-16.6% | $17.1M+14.4% | $15.0M+2108.1% | -$745K |
| Retained Earnings | -$206.0M-19.5% | -$172.4M-31.0% | -$131.6M-29.2% | -$101.8M-39.9% | -$72.8M-27.9% | -$56.9M-43.9% | -$39.6M-50.1% | -$26.4M-82.0% | -$14.5M-209.7% | -$4.7M-524.7% | -$748K |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
MBRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$25.4M | -$22.7M+4.7% | -$23.9M-1.1% | -$23.6M+14.6% | -$27.6M-45.8% | -$19.0M-6.6% | -$17.8M-3.3% | -$17.2M-40.9% | -$12.2M-66.6% | -$7.3M-94.5% | -$3.8M | N/A |
| Capital Expenditures | N/A | $0-100.0% | $13K-89.5% | $124K+85.1% | $67K+252.6% | $19K-94.9% | $376K+623.1% | $52K-87.5% | $417K+1389.3% | $28K+33.3% | $21K | N/A |
| Free Cash Flow | N/A | -$22.7M+4.8% | -$23.9M-0.7% | -$23.7M+14.4% | -$27.7M-46.1% | -$19.0M-4.5% | -$18.1M-5.2% | -$17.3M-36.7% | -$12.6M-71.7% | -$7.4M-94.2% | -$3.8M | N/A |
| Investing Cash Flow | $0 | $0+100.0% | -$13K+89.5% | -$124K-85.1% | -$67K-252.6% | -$19K+94.9% | -$374K-633.3% | -$51K+87.8% | -$417K-1389.3% | -$28K+76.9% | -$121K | N/A |
| Financing Cash Flow | $25.1M | $27.3M+488.7% | $4.6M+11.9% | $4.1M+18104.3% | -$23K-100.0% | $74.7M+231.4% | $22.5M+8.1% | $20.9M+73.1% | $12.0M+19.7% | $10.1M+13.5% | $8.9M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MBRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -223.6%+8.8pp | -232.4%-136.2pp | -96.3%-40.6pp | -55.6%-35.5pp | -20.1%+77.6pp | -97.7%-12.9pp | -84.8%-1.6pp | -83.2%-25.9pp | -57.3%-31.0pp | -26.2% | N/A |
| Return on Assets | -151.7%+2.2pp | -153.9%-76.0pp | -77.9%-27.3pp | -50.5%-31.6pp | -18.9%+40.9pp | -59.8%-7.5pp | -52.3%+8.3pp | -60.6%-10.3pp | -50.3%-26.4pp | -23.9% | N/A |
| Current Ratio | 1.41+0.4x | 0.97-2.9x | 3.86-5.6x | 9.46-10.6x | 20.02+14.1x | 5.89+2.1x | 3.78+1.7x | 2.06-1.7x | 3.75-0.1x | 3.88+3.8x | 0.04 |
| Debt-to-Equity | 0.470.0x | 0.51+0.1x | 0.39+0.3x | 0.100.0x | 0.06-0.6x | 0.630.0x | 0.62+0.2x | 0.37+0.2x | 0.140.0x | 0.10 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Moleculin Biotec Ranks
Frequently Asked Questions
What is Moleculin Biotec's annual revenue?
Moleculin Biotec (MBRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Moleculin Biotec profitable?
No, Moleculin Biotec (MBRX) reported a net income of -$33.6M in fiscal year 2025.
What is Moleculin Biotec's EBITDA?
Moleculin Biotec (MBRX) had EBITDA of -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Moleculin Biotec's return on equity (ROE)?
Moleculin Biotec (MBRX) has a return on equity of -223.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Moleculin Biotec's free cash flow?
Moleculin Biotec (MBRX) recorded an outflow of $22.7M in free cash flow during fiscal year 2025. This represents a 4.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Moleculin Biotec's operating cash flow?
Moleculin Biotec (MBRX) recorded an outflow of $22.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Moleculin Biotec's total assets?
Moleculin Biotec (MBRX) had $22.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Moleculin Biotec's capital expenditures?
Moleculin Biotec (MBRX) reported no capital expenditure during fiscal year 2025.
How much does Moleculin Biotec spend on research and development?
Moleculin Biotec (MBRX) invested $15.9M in research and development during fiscal year 2025.
What is Moleculin Biotec's current ratio?
Moleculin Biotec (MBRX) had a current ratio of 1.41 as of fiscal year 2025, which is considered adequate.
What is Moleculin Biotec's debt-to-equity ratio?
Moleculin Biotec (MBRX) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Moleculin Biotec's return on assets (ROA)?
Moleculin Biotec (MBRX) had a return on assets of -151.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Moleculin Biotec's cash runway?
Based on fiscal year 2025 data, Moleculin Biotec (MBRX) had $8.9M in cash against an annual operating cash burn of $22.7M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Moleculin Biotec's Altman Z-Score?
Moleculin Biotec (MBRX) has an Altman Z-Score of -15.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Moleculin Biotec's Piotroski F-Score?
Moleculin Biotec (MBRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Moleculin Biotec's earnings high quality?
Moleculin Biotec (MBRX) reported a net loss of $33.6M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.